C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

C4X Discovery Holdings PLC
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

C4X Discovery Holdings PLC
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
C4X Discovery Holdings PLC
LSE:C4XD
Common Shares Outstanding
ÂŁ252.2m
CAGR 3-Years
4%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Common Shares Outstanding
ÂŁ859.2m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Common Shares Outstanding
ÂŁ84.5m
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Common Shares Outstanding
ÂŁ153m
CAGR 3-Years
34%
CAGR 5-Years
35%
CAGR 10-Years
32%
Ergomed PLC
LSE:ERGO
Common Shares Outstanding
ÂŁ50.8m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Common Shares Outstanding
ÂŁ680.4m
CAGR 3-Years
0%
CAGR 5-Years
22%
CAGR 10-Years
38%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

What is C4X Discovery Holdings PLC's Common Shares Outstanding?
Common Shares Outstanding
252.2m GBP

Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Common Shares Outstanding amounts to 252.2m GBP.

What is C4X Discovery Holdings PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
34%

Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for C4X Discovery Holdings PLC have been 4% over the past three years , 34% over the past five years .

Back to Top